---
title: "Povorcitinib (JAK1 inhibitor) meets F‑VASI75 in two phase 3 STOP‑V trials for nonsegmental vitiligo"
id: "nature-1-povorcitinib-for-nonsegmental-vitiligo-two-randomized-controlled-phase-3-stop-v"
canonical_url: "https://medichelpline.com/clinical-feed/nature-1-povorcitinib-for-nonsegmental-vitiligo-two-randomized-controlled-phase-3-stop-v"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "Nature Medicine"
source_url: "https://www.nature.com/articles/s41591-026-04739-2"
published_at: "2026-11-02T11:28:10.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Povorcitinib (JAK1 inhibitor) meets F‑VASI75 in two phase 3 STOP‑V trials for nonsegmental vitiligo
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-1-povorcitinib-for-nonsegmental-vitiligo-two-randomized-controlled-phase-3-stop-v
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** Nature Medicine
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41591-026-04739-2)
- **Published At:** 2026-11-02T11:28:10.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Two parallel, randomized, double-blind, placebo-controlled phase 3 trials (STOP‑V1 and STOP‑V2) evaluated once-daily **povorcitinib** 30 mg in adults with moderate-to-severe **nonsegmental vitiligo** (NSV). - STOP‑V1 enrolled 467 patients; STOP‑V2 enrolled 449 patients, and both trials reported 52-week primary results. - The prespecified primary endpoint was ≥75% improvement in facial Vitiligo Area Scoring Index (**F‑VASI75**) at week 52; both trials met this endpoint versus placebo. - STOP‑V1 response rates: 18.9% with povorcitinib vs 6.8% with placebo (odds ratio 3.1; 95% CI 1.6–5.9; P = 0.0003), as the study team reported. - STOP‑V2 response rates: 18.9% with povorcitinib vs 3.1% with placebo (odds ratio 7.5; 95% CI 3.0–18.6; P < 0.0001), investigators reported. - Overall tolerability was similar between treatment and placebo arms; any-treatment-emergent adverse events occurred in roughly two-thirds of participants in both groups across studies. - Most common treatment-emergent adverse events with povorcitinib included nasopharyngitis (≈11% in both trials), acne (~10.7–10.8%), and upper respiratory tract infection (6.9% in STOP‑V1; 14.0% in STOP‑V2). - Serious TEAEs were generally single events; class-specific JAK inhibitor adverse events were absent or rare in these reports. - The trials support once-daily povorcitinib as an effective systemic option for adults with moderate-to-severe NSV, per the authors; ClinicalTrials.gov identifiers are NCT06113445 and NCT06113471. - The source did not report long-term safety beyond 52 weeks, head-to-head comparisons with topical ruxolitinib, nor efficacy in adolescents; those questions remain open.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41591-026-04739-2#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Medicine](https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg) ](https://www.nature.com/nm) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-026-04739-2) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nm/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nm/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nm/news-and-comment) * [ Podcasts ](https://www.nature.com/nm/podcast) * [ Current issue ](https://www.nature.com/nm/current-issue) * [ Collections ](https://www.nature.com/nm/collections) * [Follow us on Facebook ](https://www.facebook.com/Nature-Medicine-193691346949/) * [Follow us on X ](https://twitter.com/naturemedicine) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nm/aims) * [ Journal Information ](https://www.nature.com/nm/journal-information) * [ Editors ](https://www.nature.com/nm/editors) * [ Journal Metrics ](https://www.nature.com/nm/journal-impact) * [ Research Cross-Journal Editorial Team ](https://www.nature.com/nm/research-cross-journal-editorial-team) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nm/reviews-cross-journal-editorial-team) * [ Statistical Advisory Panel ](https://www.nature.com/nm/statistics-advisory-panel) * [ Our publishing models ](https://www.nature.com/nm/our-publishing-models) * [ Editorial Values Statement ](https://www.nature.com/nm/editorial-values-statement) * [ Editorial Policies ](https://www.nature.com/nm/editorial-policies) * [ Content Types ](https://www.nature.com/nm/content) * [ Web Feeds ](https://www.nature.com/nm/web-feeds) * [ Contact ](https://www.nature.com/nm/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ Submission Guidelines ](https://www.nature.com/nm/submission-guidelines) * [ For Reviewers ](https://www.nature.com/nm/for-reviewers) * [ Language editing services ](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022) * [Open access funding](https://www.nature.com/nm/open-access-funding) * [Submit manuscript ](https://mts-nmed.nature.com/cgi-bin/main.plex) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) 1. [nature](https://www.nature.com/) 2. [nature medicine](https://www.nature.com/nm) 3. [articles](https://www.nature.com/nm/articles?type=article) 4. article Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials [ Download PDF ](https://www.nature.com/articles/s41591-026-04739-2.pdf) [ Download PDF ](https://www.nature.com/articles/s41591-026-04739-2.pdf) * Article * [Open access](https://www.springernature.com/gp/open-science/about/the-fundamentals-of-open-access-and-open-research) * Published: 02 November 2026 # Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials * [Khaled Ezzedine](https://www.nature.com/articles/s41591-026-04739-2#auth-Khaled-Ezzedine-Aff1) [ORCID: orcid.org/0000-0002-5468-4589](https://orcid.org/0000-0002-5468-4589)[1](https://www.nature.com/articles/s41591-026-04739-2#Aff1), * [Harvey Lui](https://www.nature.com/articles/s41591-026-04739-2#auth-Harvey-Lui-Aff2) [ORCID: orcid.org/0000-0002-0584-5980](https://orcid.org/0000-0002-0584-5980)[2](https://www.nature.com/articles/s41591-026-04739-2#Aff2), * [Viktoria Eleftheriadou](https://www.nature.com/articles/s41591-026-04739-2#auth-Viktoria-Eleftheriadou-Aff3-Aff4-Aff5)[3](https://www.nature.com/articles/s41591-026-04739-2#Aff3),[4](https://www.nature.com/articles/s41591-026-04739-2#Aff4),[5](https://www.nature.com/articles/s41591-026-04739-2#Aff5), * [Seemal R. Desai](https://www.nature.com/articles/s41591-026-04739-2#auth-Seemal_R_-Desai-Aff6-Aff7)[6](https://www.nature.com/articles/s41591-026-04739-2#Aff6),[7](https://www.nature.com/articles/s41591-026-04739-2#Aff7), * [Thierry Passeron](https://www.nature.com/articles/s41591-026-04739-2#auth-Thierry-Passeron-Aff8-Aff9)[8](https://www.nature.com/articles/s41591-026-04739-2#Aff8),[9](https://www.nature.com/articles/s41591-026-04739-2#Aff9), * [Julien Ringuet](https://www.nature.com/articles/s41591-026-04739-2#auth-Julien-Ringuet-Aff10-Aff11) [ORCID: orcid.org/0000-0002-6773-4645](https://orcid.org/0000-0002-6773-4645)[10](https://www.nature.com/articles/s41591-026-04739-2#Aff10),[11](https://www.nature.com/articles/s41591-026-04739-2#Aff11), * [Nanja van Geel](https://www.nature.com/articles/s41591-026-04739-2#auth-Nanja-Geel-Aff12-Aff13)[12](https://www.nature.com/articles/s41591-026-04739-2#Aff12),[13](https://www.nature.com/articles/s41591-026-04739-2#Aff13), * [Albert Wolkerstorfer](https://www.nature.com/articles/s41591-026-04739-2#auth-Albert-Wolkerstorfer-Aff14)[14](https://www.nature.com/articles/s41591-026-04739-2#Aff14), * [Charles Lynde](https://www.nature.com/articles/s41591-026-04739-2#auth-Charles-Lynde-Aff15-Aff16-Aff17) [ORCID: orcid.org/0000-0001-9163-5463](https://orcid.org/0000-0001-9163-5463)[15](https://www.nature.com/articles/s41591-026-04739-2#Aff15),[16](https://www.nature.com/articles/s41591-026-04739-2#Aff16),[17](https://www.nature.com/articles/s41591-026-04739-2#Aff17), * [Matthias Augustin](https://www.nature.com/articles/s41591-026-04739-2#auth-Matthias-Augustin-Aff18) [ORCID: orcid.org/0000-0002-4026-8728](https://orcid.org/0000-0002-4026-8728)[18](https://www.nature.com/articles/s41591-026-04739-2#Aff18), * [José Luis López-Estebaranz](https://www.nature.com/articles/s41591-026-04739-2#auth-Jos__Luis-L_pez_Estebaranz-Aff19)[19](https://www.nature.com/articles/s41591-026-04739-2#Aff19), * [Pearl Grimes](https://www.nature.com/articles/s41591-026-04739-2#auth-Pearl-Grimes-Aff20)[20](https://www.nature.com/articles/s41591-026-04739-2#Aff20), * [David Rosmarin](https://www.nature.com/articles/s41591-026-04739-2#auth-David-Rosmarin-Aff21)[21](https://www.nature.com/articles/s41591-026-04739-2#Aff21), * [Kurt Brown](https://www.nature.com/articles/s41591-026-04739-2#auth-Kurt-Brown-Aff22)[22](https://www.nature.com/articles/s41591-026-04739-2#Aff22), * [Shaoceng Wei](https://www.nature.com/articles/s41591-026-04739-2#auth-Shaoceng-Wei-Aff22)[22](https://www.nature.com/articles/s41591-026-04739-2#Aff22), * [Sunanda Karanam](https://www.nature.com/articles/s41591-026-04739-2#auth-Sunanda-Karanam-Aff22)[22](https://www.nature.com/articles/s41591-026-04739-2#Aff22), * [Deanna Kornacki](https://www.nature.com/articles/s41591-026-04739-2#auth-Deanna-Kornacki-Aff22)[22](https://www.nature.com/articles/s41591-026-04739-2#Aff22) & * … * [Amit G. Pandya](https://www.nature.com/articles/s41591-026-04739-2#auth-Amit_G_-Pandya-Aff23)[23](https://www.nature.com/articles/s41591-026-04739-2#Aff23) Show authors [_Nature Medicine_](https://www.nature.com/nm) (2026) [Cite this article](https://www.nature.com/articles/s41591-026-04739-2#citeas) Save article [ View saved research ](https://www.nature.com/saved-research) ## Abstract There is an unmet need for repigmentation therapies for patients with nonsegmental vitiligo (NSV) who are candidates for systemic therapy. Here, 52-week primary results are reported from two parallel phase 3, randomized, double-blind, placebo-controlled trials of once-daily povorcitinib (oral, highly selective JAK1 inhibitor) 30 mg in adults with moderate-to-severe NSV (STOP-V1 and STOP-V2). STOP-V1 and STOP-V2 enrolled 467 and 449 patients, respectively. In both studies, the primary endpoint of ≥75% improvement in the facial Vitiligo Area Scoring Index (F-VASI75) at week 52 was met, demonstrating statistically significant and clinically meaningful repigmentation with povorcitinib versus placebo (STOP-V1: 18.9% versus 6.8%; odds ratio, 3.1; 95% confidence interval 1.6–5.9; _P_ = 0.0003; STOP-V2: 18.9% versus 3.1%; odds ratio, 7.5; 95% confidence interval 3.0–18.6; _P_ < 0.0001). Povorcitinib was well tolerated; the percentage of patients with any treatment-emergent adverse event (TEAE) was similar between the povorcitinib and placebo groups in both studies (STOP-V1/STOP-V2, 68.7%/66.7% versus 63.7%/62.7%). The most common TEAEs with povorcitinib were nasopharyngitis (STOP-V1/STOP-V2, 11.2%/11.3% versus placebo, 9.8%/11.1%), acne (10.7%/10.8% versus 3.0%/2.2%) and upper respiratory tract infection (6.9%/14.0% versus 9.0%/10.7%). Serious TEAEs were generally single events, and Janus kinase inhibitor class-specific TEAEs were absent or rare. These results support once-daily povorcitinib as an effective and well-tolerated systemic treatment for adults with moderate-to-severe NSV. ClinicalTrials.gov identifiers: [NCT06113445](https://clinicaltrials.gov/study/NCT06113445), [NCT06113471](https://clinicaltrials.gov/study/NCT06113471). ### Explore related subjects Discover the latest articles and news in related subjects. * [Autoimmune diseases](https://www.nature.com/subjects/autoimmune-diseases) * [Inflammatory diseases](https://www.nature.com/subjects/inflammatory-diseases) * [Randomized controlled trials](https://www.nature.com/subjects/randomized-controlled-trials) * [Skin manifestations](https://www.nature.com/subjects/skin-manifestations) * [Vitiligo Management and Pathogenesis Insights](https://www.nature.com/subjects/vitiligo-management-and-pathogenesis-insights) ## Main Vitiligo is a chronic, autoimmune disease characterized by skin depigmentation resulting from the loss of melanocytes[1](https://www.nature.com/articles/s41591-026-04739-2#ref-CR1 "Bergqvist, C. & Ezzedine, K. Vitiligo: a review. Dermatology 236, 571–592 \(2020\)."),[2](https://www.nature.com/articles/s41591-026-04739-2#ref-CR2 "Ezzedine, K., Eleftheriadou, V., Whitton, M. & van Geel, N. Vitiligo. Lancet 386, 74–84 \(2015\)."). The global prevalence of diagnosed vitiligo is approximately 0.4%, with rates varying geographically and by age group[3](https://www.nature.com/articles/s41591-026-04739-2#ref-CR3 "Akl, J. et al. Estimating the burden of vitiligo: a systematic review and modelling study. Lancet Public Health 9, e386–e396 \(2024\)."),[4](https://www.nature.com/articles/s41591-026-04739-2#ref-CR4 "Haulrig, M. B. et al. The global epidemiology of vitiligo: a systematic review and meta-analysis of the incidence and prevalence. J. Eur. Acad. Dermatol. Venereol. 3, 1410–1419 \(2024\)."). Patients with segmental (unilateral distribution) and nonsegmental vitiligo (NSV; bilateral distribution) have distinct clinical characteristics and disease courses; NSV accounts for up to 90% of vitiligo cases[5](https://www.nature.com/articles/s41591-026-04739-2#ref-CR5 "Taieb, A. & Picardo, M. Clinical practice. Vitiligo. N. Engl. J. Med. 360, 160–169 \(2009\)."). Segmental vitiligo affects less body surface area (BSA) and responds best to treatment within 2 years of onset, after which other modalities (for example, surgery) may be considered[6](https://www.nature.com/articles/s41591-026-04739-2#ref-CR6 "Shen, N. et al. Segmental vitiligo: a distinct entity with unique pathogenesis and clinical implications. J. Invest. Dermatol. 146, 1501–1513 \(2026\)."). Thus, large, controlled trials generally focus on NSV. Vitiligo is associated with other autoimmune conditions, such as thyroid disorders and type 1 diabetes[7](https://www.nature.com/articles/s41591-026-04739-2#ref-CR7 "Rios-Duarte, J. A., Sanchez-Zapata, M. J. & Silverberg, J. I. Association of vitiligo with multiple cutaneous and extra-cutaneous autoimmune diseases: a nationwide cross-sectional study. Arch. Dermatol. Res. 315, 2597–2603 \(2023\)."); psychosocial comorbidities, including depression, anxiety, suicidality and stigmatization[8](https://www.nature.com/articles/s41591-026-04739-2#ref-CR8 "Ezzedine, K. et al. Psychosocial effects of vitiligo: a systematic literature review. Am. J. Clin. Dermatol. 22, 757–774 \(2021\)."); and an overall reduction in quality of life[9](https://www.nature.com/articles/s41591-026-04739-2#ref-CR9 "Bibeau, K. et al. Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study. JAMA Dermatol. 159, 1124–1128 \(2023\)."),[10](https://www.nature.com/articles/s41591-026-04739-2#ref-CR10 "Picardo, M. et al. The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes. J. Eur. Acad. Dermatol. Venereol. 36, 1507–1523 \(2022\)."). Psychosocial and quality-of-life burden are further impacted by increased disease extent and/or visibility of lesions (for example, facial or hand involvement) and are greater in patients with darker skin types[9](https://www.nature.com/articles/s41591-026-04739-2#ref-CR9 "Bibeau, K. et al. Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study. JAMA Dermatol. 159, 1124–1128 \(2023\)."),[10](https://www.nature.com/articles/s41591-026-04739-2#ref-CR10 "Picardo, M. et al. The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes. J. Eur. Acad. Dermatol. Venereol. 36, 1507–1523 \(2022\)."),[11](https://www.nature.com/articles/s41591-026-04739-2#ref-CR11 "Bibeau, K. et al. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J. Eur. Acad. Dermatol. Venereol. 36, 1831–1844 \(2022\)."). The 2026 INTERCEPT study consensus defines vitiligo severity beyond disease extent, including factors of disease activity, lesion visibility and psychosocial burden, among others, as determinants for recommending systemic therapy[12](https://www.nature.com/articles/s41591-026-04739-2#ref-CR12 "Eleftheriadou, V. et al. Definition of severity and relapse for vitiligo: an international consensus statement. JAMA Dermatol. 162, 515–524 \(2026\)."). The JAK–STAT signaling pathway has a critical role in the pathophysiology of vitiligo[13](https://www.nature.com/articles/s41591-026-04739-2#ref-CR13 "McElroy, J. et al. Understanding the mechanism of disease of vitiligo and the impact on clinical management. J. Dermatol. Physician Assist. 19, 28–35 \(2025\)."). Activation of the JAK–STAT pathway leads to the production of CXCL10, which promotes further recruitment of cytotoxic CD8+ T cells responsible for the destruction of melanocytes[14](https://www.nature.com/articles/s41591-026-04739-2#ref-CR14 "Harris, J. E. et al. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T-cell accumulation in the skin. J. Invest. Dermatol. 132, 1869–1876 \(2012\)."),[15](https://www.nature.com/articles/s41591-026-04739-2#ref-CR15 "Rashighi, M. et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci. Transl. Med. 6, 223ra223 \(2014\)."),[16](https://www.nature.com/articles/s41591-026-04739-2#ref-CR16 "Richmond, J. M. et al. Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease. J. Invest. Dermatol. 137, 350–358 \(2017\)."). Ruxolitinib (selective JAK1 and JAK2 inhibitor) cream was the first treatment approved for the repigmentation of NSV[17](https://www.nature.com/articles/s41591-026-04739-2#ref-CR17 "Seneschal, J. et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force–part 2: specific treatment recommendations. J. Eur. Acad. Dermatol. Venereol. 37, 2185–2195 \(2023\).") in several geographic regions, including the USA, Canada, the European Union and the UK. Ruxolitinib cream is indicated in patients aged ≥12 years for twice-daily topical treatment of affected areas up to 10% BSA[18](https://www.nature.com/articles/s41591-026-04739-2#ref-CR18 "Opzelura \(ruxolitinib cream\) \(Incyte Biosciences Distribution B.V., 2026\)."),[19](https://www.nature.com/articles/s41591-026-04739-2#ref-CR19 "Opzelura \(ruxolitinib cream\) \(Incyte Biosciences UK Ltd, 2026\)."),[20](https://www.nature.com/articles/s41591-026-04739-2#ref-CR20 "Opzelura \(ruxolitinib cream\) \(Incyte Corporation, 2026\)."),[21](https://www.nature.com/articles/s41591-026-04739-2#ref-CR21 "Opzelura \(ruxolitinib cream\) product monograph \(Incyte Corporation and Innomar Strategies, 2025\)."). There is a need for effective and well-tolerated therapies for patients with NSV who are candidates for systemic therapy (that is, moderate-to-severe NSV[12](https://www.nature.com/articles/s41591-026-04739-2#ref-CR12 "Eleftheriadou, V. et al. Definition of severity and relapse for vitiligo: an international consensus statement. JAMA Dermatol. 162, 515–524 \(2026\).")). Povorcitinib is an oral, highly selective JAK1 inhibitor[22](https://www.nature.com/articles/s41591-026-04739-2#ref-CR22 "Zhuo, J. et al. Discovery of the orally bioavailable isoform selective Janus kinase 1 \(JAK1\) compound povorcitinib \(INCB054707\) for the treatment of inflammatory and autoimmune diseases. J. Med. Chem. 69, 12830–12852 \(2026\).") currently being evaluated as a potential treatment for autoimmune and inflammatory diseases, including vitiligo. In a phase 2, randomized, dose-ranging study in adults with extensive NSV (≥8% affected BSA), povorcitinib was well tolerated and significantly improved facial and total body repigmentation with 15, 45 and 75 mg once-daily (QD) dosing versus placebo at 6 months, with 27.7%, 36.4% and 29.4% improvement from baseline in facial Vitiligo Area Scoring Index (F-VASI) respectively, versus 5.1% for placebo, and 19.1%, 17.8% and 15.7% improvement in total VASI (T-VASI) versus −2.3% for placebo[23](https://www.nature.com/art
## Related Clinical Research

- [Diabetic ketoacidosis admissions fell 6.9% annually in a 10-year Norwegian cohort](https://medichelpline.com/clinical-feed/plos-one-18-trends-and-outcomes-in-diabetic-ketoacidosis-a-10-year-retrospective-study-at-a.md)
- [North West London Diabetes Cohort: multiethnic EHR resource for diabetes complications research](https://medichelpline.com/clinical-feed/bmj-open-2-large-scale-multiethnic-electronic-health-record-resource-for-diabetes.md)
- [Intimate partner violence among first-generation Latino immigrants in Southern New Mexico](https://medichelpline.com/clinical-feed/plos-one-16-the-lived-experience-of-intimate-partner-violence-among-first-generation-latino.md)
- [Cost-effectiveness and cost-utility of integrated mental health video consultations (PROVIDE-C)](https://medichelpline.com/clinical-feed/pubmed-42462930.md) (DOI: 10.1016/j.jad.2026.122280)
- [Medical News Today report: three antidepressants linked to better long-term control of depression](https://medichelpline.com/clinical-feed/medical-news-today-0-3-antidepressants-may-be-best-for-long-term-depression-treatment.md)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.